ArticleWorld journal of hepatology2025
Assessing the role of Mac-2 binding protein glycosylation isomer in the management of patients with chronic hepatitis B.
Article in World journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Mac-2 binding protein glycosylated isomer (M2BPGi) is a serum marker for fibrosis that correlates with the fibrosis stages in various liver diseases.
aimTo examine the M2BPGi's threshold for staging fibrosis in patients with chronic hepatitis B (CHB), and its changes during treatment.
methodsThis was a prospective, longitudinal study. A total of 348 eligible patients were recruited from the Hepatology Department, Medic Medical Center between March 2020 and December 2023. Liver enzyme tests, platelet counts, M2BPGi levels, and FibroScan were conducted at baseline and at 3-month intervals until six months post-treatment. Correlation plots of M2BPGi, FibroScan, and the other parameters were generated. Receiver operating characteristic curves were constructed for M2BPGi and the other parameters to evaluate their performance.
resultsM2BPGi levels correlated well with FibroScan results and increased as the fibrosis stage advanced. The median M2BPGi levels at the different stages of fibrosis showed statistically significant differences. The cut-off values of M2BPGi for diagnosing significant fibrosis (F ≥ 2), advanced fibrosis (F3), and cirrhosis (F4) were determined to be 1.08, 1.4, and 1.52, respectively. In the context of fibrosis regression in CHB patients during the first 6-month of treatment, M2BPGi levels appeared to decrease before this pattern occurred in the FibroScan results.
conclusionM2BPGi levels were strongly correlated with FibroScan. M2BPGi can be used to assess liver fibrosis, and to serve as a tool for monitoring fibrosis regression in CHB patients undergoing treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.